Details of the Drug

General Information of Drug (ID: DMCYVDT)

• Drug Name: Chlorzoxazone
• Synonyms: Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one

Indication

Disease Entry	ICD 11	Status	REF
Acute pain	MG31	Approved	[1], [2], [3]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 169.56
  Topological Polar Surface Area (xlogp); 1.8
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [4]
  Metabolism: The drug is metabolized via the liver [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 196.38089 micromolar/kg/day [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.25 mg/mL [4]
• Chemical Identifiers:
  Formula: C7H4ClNO2
  IUPAC Name: 5-chloro-3H-1,3-benzoxazol-2-one
  Canonical SMILES: C1=CC2=C(C=C1Cl)NC(=O)O2
  InChI: InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
  InChIKey: TZFWDZFKRBELIQ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2733
  ChEBI ID: CHEBI:3655
  CAS Number: 95-25-0
  DrugBank ID: DB00356
  TTD ID: D08ZEB
  VARIDT ID: DR00571
  INTEDE ID: DR0312
  ACDINA ID: D00127

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel (KCN)	TTMNI76	NOUNIPROTAC	Activator	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[12], [13]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Chlorzoxazone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Oliceridine.	Acute pain [MG31]	[57]

Coadministration of a Drug Treating the Disease Different from Chlorzoxazone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[58]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[59]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[60]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Dihydrocodeine.	Chronic pain [MG30]	[61]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Olopatadine.	Conjunctiva disorder [9A60]	[62]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Alfentanil.	Corneal disease [9A76-9A78]	[57]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Remifentanil.	Corneal disease [9A76-9A78]	[57]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Ethanol.	Cystitis [GC00]	[62]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Esketamine.	Depression [6A70-6A7Z]	[58]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Cannabidiol.	Epileptic encephalopathy [8A62]	[63]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Brimonidine.	Glaucoma [9C61]	[64]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Chlorzoxazone caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[65]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[66]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Abacavir	DMMN36E	Minor	Increased plasma concentrations of Chlorzoxazone and Abacavir due to competitive inhibition of the same metabolic pathway.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[69]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[70]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Methotrexate.	Leukaemia [2A60-2B33]	[63]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Chlorzoxazone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[58]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[71]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Idelalisib.	Mature B-cell leukaemia [2A82]	[72]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Clofarabine.	Mature B-cell lymphoma [2A85]	[73]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[74]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Lasmiditan.	Migraine [8A80]	[75]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Flibanserin.	Mood disorder [6A60-6E23]	[76]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[61]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Apraclonidine.	Optic nerve disorder [9C40]	[64]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Pentazocine.	Pain [MG30-MG3Z]	[57]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Butorphanol.	Pain [MG30-MG3Z]	[57]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Oxymorphone.	Pain [MG30-MG3Z]	[57]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Levorphanol.	Pain [MG30-MG3Z]	[57]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Dezocine.	Pain [MG30-MG3Z]	[57]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Nalbuphine.	Pain [MG30-MG3Z]	[57]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Buprenorphine.	Pain [MG30-MG3Z]	[77]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Hydrocodone.	Pain [MG30-MG3Z]	[57]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Meperidine.	Pain [MG30-MG3Z]	[57]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Oxycodone.	Pain [MG30-MG3Z]	[57]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Leflunomide.	Rheumatoid arthritis [FA20]	[70]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Fentanyl.	Sensation disturbance [MB40]	[57]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Chlorzoxazone and Sufentanil.	Sensation disturbance [MB40]	[57]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[63]
Disulfiram	DMCL2OK	Moderate	Decreased metabolism of Chlorzoxazone caused by Disulfiram mediated inhibition of CYP450 enzyme.	Substance abuse [6C40]	[78]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Chlorzoxazone and Naltrexone.	Substance abuse [6C40]	[79]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Chlorzoxazone and Tizanidine.	Tonus and reflex abnormality [MB47]	[80]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlorzoxazone 500 mg tablet	500 mg	Oral Tablet	Oral
Chlorzoxazone 250 mg tablet	250 mg	Oral Tablet	Oral
Chlorzoxazone 375 mg tablet	375 mg	Oral Tablet	Oral
Chlorzoxazone 750 mg tablet	750 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2322).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040113.
• [4] BDDCS applied to over 900 drugs
• [5] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
• [8] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [9] Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
• [10] Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
• [11] Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82.
• [12] Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
• [13] The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
• [14] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [15] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [16] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [17] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [18] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [19] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [20] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [21] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [22] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [23] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [24] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [25] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [26] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [27] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [28] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [29] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [30] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [31] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [32] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [33] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [34] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [35] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [36] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [37] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [38] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [39] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [40] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [41] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [42] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [43] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [44] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [45] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [46] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [47] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [48] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [49] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [50] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [51] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [52] Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
• [53] acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
• [54] Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
• [55] Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
• [56] Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
• [57] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [58] Cerner Multum, Inc. "Australian Product Information.".
• [59] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [60] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [61] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [62] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [63] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [64] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [65] Leclercq I, Desager JP, Horsmans Y "Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress." Clin Pharmacol Ther 64 (1998): 144-9. [PMID: 9728894]
• [66] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [67] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [68] Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
• [69] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [70] Canadian Pharmacists Association.
• [71] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [72] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [73] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [74] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [75] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [76] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [77] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [78] Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH "Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1." Clin Pharmacol Ther 53 (1993): 643-50. [PMID: 8513656]
• [79] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [80] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.